Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Cervical and other gynecologic cancers
Pembrolizumab (PD-1) + Chemotherapy Sustains 5-Year OS Benefit in 1L Advanced Cervical Cancer
Pembrolizumab is a PD-1–blocking antibody added to platinum–taxane chemotherapy, with or without bevacizumab, for previously untreated persistent, recurrent, or metastatic cervical cancer; in the US, this combination…
- Trial result
Kidney cancer
Improving HRQoL Correlates With Longer PFS/OS in LITESPARK-005
Belzutifan is an oral hypoxia-inducible factor-2α (HIF-2α) inhibitor compared with everolimus (mTOR inhibitor) in the randomized Phase 3 LITESPARK-005 trial (NCT04195750) in previously treated advanced clear cell RCC…
NCT04195750 - Trial result
Kidney cancer
Tivozanib (VEGFR TKI) Beats Tivozanib+nivolumab in post-ICI mRCC, extending 2L PFS
Tivozanib is an oral VEGFR-1/2/3 tyrosine kinase inhibitor (TKI); TiNivo-2 randomized post–immune checkpoint inhibitor (ICI) metastatic RCC patients to standard-dose tivozanib 1.34mg (21/28 days) vs reduced-dose…
NCT04987203 - Trial result
Kidney cancer
Casdatifan (HIF-2α inhibitor) Monotherapy in Late-Line ccRCC Shows Class-On-Target Anemia/Hypoxia With Low Discontinuation
Casdatifan is a potent, selective oral hypoxia-inducible factor-2α (HIF-2α) inhibitor evaluated as monotherapy in the ongoing ARC-20 platform study (NCT05536141) in metastatic clear cell RCC previously treated with…
NCT05536141 - Trial result Spotlight
Ovarian cancer
Pembrolizumab (PD-1) + chemo → maintenance pembrolizumab + olaparib (PARP) extends PFS in BRCA–wild-type ovarian cancer
Pembrolizumab is an anti–PD-1 antibody and olaparib is a PARP inhibitor; in KEYLYNK-001 (ENGOT-OV43/GOG-3036; NCT03740165), patients with newly diagnosed stage III–IV BRCA1/2 non-mutated epithelial ovarian/primary…
NCT03740165 - Trial result Spotlight
Multiple myeloma
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma
Teclistamab is a BCMA-targeting T-cell–redirecting bispecific antibody tested as a fixed-duration “immune interception” strategy in the randomized Phase 2 ImmunoPRISM trial (NCT05469893) versus…
NCT05469893 - Trial result
Stomach and esophageal cancer
Camrelizumab (PD-1) + nimotuzumab (EGFR mAb) delivers 32.6% ORR in 2L advanced ESCC
Camrelizumab is an anti–PD-1 immune checkpoint inhibitor combined with nimotuzumab, an anti-EGFR monoclonal antibody, tested in a Chinese multicenter single-arm Phase II second-line study in advanced esophageal…
NCT03766178 - New trial Spotlight
Pancreatic cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D RAS(ON) inhibitor + daraxonrasib (RMC-6236) RAS(ON) multi-selective inhibitor
Revolution Medicines’ RASolute 309 is a Phase 3, randomized, open-label study testing whether dual RAS(ON) blockade improves outcomes versus standard chemotherapy in first-line metastatic pancreatic adenocarcinoma…
NCT07805954 Registrational - New trial
Prostate cancer
Phase 2 18F-fluorthanatrace (FTT) PARP1-targeted PET tracer to predict PARPi response
Washington University School of Medicine is running a multicenter, open-label diagnostic study testing whether 18F-fluorthanatrace (18F-FTT), a PARP1-directed PET imaging tracer, can help predict response to…
NCT07723651 Exploratory - New trial
Breast cancer
Phase 2 ddCMF chemo (alkylator + antifolate + thymidylate synthase inhibitor) in older breast cancer
Memorial Sloan Kettering Cancer Center is running this Phase 2 feasibility study testing dose-dense CMF (cyclophosphamide, methotrexate, and 5‑fluorouracil) as an anthracycline-sparing alternative to AC…
NCT07768436 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 2 safusidenib erbumine mutant-IDH1 inhibitor in post-vorasidenib progressive IDH1 glioma.
Nuvation Bio’s multicenter Phase 2 study tests safusidenib erbumine (250 mg orally twice daily), a brain-penetrant small-molecule inhibitor of mutant IDH1 (including IDH1 R132) that lowers the oncometabolite…
NCT07703436 Exploratory - New trial
Brain and CNS tumors
Early Phase 1 avutometinib dual RAF/MEK inhibitor + defactinib FAK inhibitor in newly diagnosed high-grade glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is running an early-phase, open-label feasibility and safety study testing avutometinib (VS-6766), a dual RAF/MEK pathway inhibitor, plus defactinib…
NCT07778602 Exploratory - New trial
Head and neck cancer
Phase 2 pembrolizumab PD-1 inhibitor plus hypofractionated RT tests ENI nodal-sparing strategy
Medical College of Wisconsin is running this non-comparative randomized Phase 2 “INITIUM” platform in resectable, locally advanced head and neck squamous cell carcinoma (HPV-negative oropharynx and resectable oral…
NCT07773987 Exploratory - New trial
Head and neck cancer
Phase 2 ficerafusp alfa (BCA101) EGFR×TGF-β bifunctional antibody + pembrolizumab
Bicara Therapeutics is running a multicenter, open-label Phase 2 study in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma testing maintenance dosing strategies for ficerafusp…
NCT07807163 Exploratory - New trial
Head and neck cancer
Phase 2 toripalimab PD-1 (CD279) antibody “priming” before paclitaxel microtubule inhibitor in HNSCC
This Phase 2 pilot, single-arm, sequential regimen study at Barbara Ann Karmanos Cancer Institute tests whether upfront toripalimab (a PD-1 immune checkpoint–blocking monoclonal antibody; Coherus BioSciences/Junshi…
NCT07796126 Exploratory - New trial
Kidney cancer
Phase 2 Elekta Unity MR-linac MR-guided SBRT (MRgRT) for localized renal cell carcinoma
NYU Langone Health is running this single-arm Phase 2 study testing whether MRI-guided, online-adaptive stereotactic body radiation therapy (SBRT) delivered on the Elekta Unity MR-guided linear accelerator can…
NCT07767500 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Daraxonrasib (RMC-6236) RAS(ON) tri-complex inhibitor delivers 37% ORR in previously treated RAS-mutant NSCLC
Daraxonrasib (RMC-6236) is an oral, multiselective RAS(ON) tri-complex inhibitor that binds active, GTP-bound mutant and wild-type RAS isoforms; it was evaluated in the Phase 1–2 RMC-6236-001 study (NCT05379985) in…
NCT05379985 - Trial result
Non-small cell lung cancer
Durvalumab (PD-L1) + neoadjuvant chemo lifts pCR across lobectomy/sleeve/pneumonectomy in resectable NSCLC
Perioperative durvalumab, an anti–PD-L1 monoclonal antibody, was evaluated in AEGEAN, a double-blind Phase 3 trial (NCT03800134) in treatment-naïve, resectable stage II–IIIB (N2) NSCLC excluding EGFR/ALK-altered…
NCT03800134 - Trial result
Non-small cell lung cancer
Atezolizumab (PD-L1) + SBRT Fails to Improve OS—and Adds Toxicity—in High-Risk Early-Stage NSCLC (SWOG/NRG S1914)
Atezolizumab is an anti–PD-L1 monoclonal antibody added as induction, concurrent, and consolidation therapy around curative-intent stereotactic body radiation therapy (SBRT) in medically inoperable (or…
NCT04214262 - Trial result
Acute myeloid leukemia and MDS
CD123 CAR-T Delivers ~27% CR/CRi in Post-alloHCT AML With Manageable CRS/Neurotoxicity
Single-center, open-label Phase 1 dose-escalation evaluated CD123-directed CAR T cells (autologous or donor-derived allogeneic CAR-T targeting the AML/BPDCN antigen CD123) after lymphodepletion in CD123+…
NCT02159495 - Trial result
Lymphoma
Favezelimab (LAG-3 mAb) + pembrolizumab (PD-1) posts 29% ORR in PD-1–refractory cHL
Favezelimab is an anti–LAG-3 monoclonal antibody designed to deepen checkpoint blockade when combined with pembrolizumab (anti–PD-1). In the open-label MK-4280-003 Phase 1/2 study (NCT03598608), anti–PD-1–refractory…
NCT03598608 - Trial result Spotlight
Uterine (endometrial) cancer
Ribociclib (CDK4/6) + everolimus (mTOR) + letrozole (aromatase) lifts ORR only in endocrine-pretreated recurrent endometrial cancer
Everolimus (oral mTORC1 inhibitor) plus letrozole (aromatase inhibitor) was tested with vs without ribociclib (CDK4/6 inhibitor) in a randomized Phase 2 recurrent endometrial cancer trial (NCT03008408). In the…
NCT03008408 - Trial result Spotlight
Head and neck cancer
Pemetrexed (antifolate chemo) + pembrolizumab (PD-1) delivers 37.5% ORR—and 63.6% in salivary duct carcinoma—in R/M salivary gland cancer
MC200708 (NCT04895735) is a single-arm Phase II (Simon two-stage) testing pemetrexed 500mg/m² IV q3w + pembrolizumab 200mg IV q3w in recurrent/metastatic non-adenoid cystic salivary gland cancers; any number of prior…
NCT04895735 - Trial result
Kidney cancer
FTI Darlifarnib + Cabozantinib Shows 33–50% ORR in Pretreated ccRCC
Darlifarnib (KO-2806) is an investigational farnesyl transferase inhibitor that blocks RHEB farnesylation to selectively suppress mTORC1, here combined with cabozantinib in the Phase 1a/b FIT-001 trial (NCT06026410).…
NCT06026410 - Trial result Spotlight
Pancreatic cancer
L-Glutamine + Gem/Nab-P Reaches 22-Month mOS in Advanced PDAC
The Phase 1 GlutaPanc trial (NCT04634539) added oral L-glutamine—a metabolic intervention with preclinical evidence of sensitizing pancreatic cancer to chemotherapy—to first-line gemcitabine + nab-paclitaxel in…
NCT04634539 - Trial result
Pancreatic cancer
Personalized Neoantigen Vaccines Elicit T-Cell Responses in Resected PDAC, With 4.4-Year mOS
Two Phase 1 trials (NCT03956056 and NCT03122106) tested personalized synthetic long-peptide and DNA vaccines designed from each patient’s tumor neoantigens after pancreatic cancer surgery and adjuvant chemotherapy.…
NCT03956056 - New trial
Head and neck cancer
Phase 2 OSPRI tests pembrolizumab (PD‑1 inhibitor) with proton SFRT vs photon SBRT
Mayo Clinic is running this randomized Phase 2 neoadjuvant study in oral cavity squamous cell carcinoma to compare two “immune‑priming” radiation approaches added to pembrolizumab (Keytruda; an anti‑PD‑1 monoclonal…
NCT07783581 Exploratory - New trial
Bladder and urothelial cancer
Phase 1b/2 capivasertib AKT (PKB) inhibitor plus immune checkpoint inhibitor in urothelial cancer
This VA Office of Research and Development Phase 1b/2 study tests whether adding capivasertib—an oral small‑molecule AKT (protein kinase B) inhibitor from AstraZeneca—to a patient’s ongoing immune checkpoint…
NCT07793578 Exploratory - New trial
Bladder and urothelial cancer
Phase 2 LUMBER-NAC compares neoadjuvant platinum chemotherapy (DNA crosslinking) vs upfront cystectomy
Rutgers University is running this Phase 2 randomized study in luminal-subtype muscle-invasive urothelial bladder cancer (cT2N0M0) to test whether skipping neoadjuvant systemic therapy is feasible and oncologically…
NCT07762586 Exploratory - New trial
Breast cancer
Phase 2 DETENTE-1 tests pembrolizumab PD‑1 inhibitor with/without carbo‑taxane neoadjuvant therapy.
UT Southwestern’s Phase 2 randomized pilot study (DETENTE-1) evaluates whether tailoring neoadjuvant therapy can increase pathologic complete response (pCR) in treatment-naive stage I TNBC (T1a–T1c, M0) before…
NCT07786428 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.